(Q46519032)

English

Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials

scientific article published in July 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

venous thromboembolism

1 reference

based on heuristic

inferred from title

author name string

G Raskob

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

H Büller

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

M Prins

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

A Segers

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

M Shi

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

L Schwocho

6

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

R van Kranen

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

M Mercuri

8

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

Hokusai-VTE Investigators

9

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

publication date

1 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

Journal of Thrombosis and Haemostasis

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

11

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

1287-1294

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Idraparinux versus standard therapy for venous thromboembolic disease

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Extended prophylaxis of venous thromboembolism with idraparinux

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Oral rivaroxaban for symptomatic venous thromboembolism

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Bias in analytic research

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Warfarin therapy in patients with venous thromboembolism: Patterns of use and predictors of clinical outcomes

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12230

21 January 2018

Identifiers

10.1111/JTH.12230

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/23574579

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46519032&oldid=2115745298"